explore -WSS

explore

author：explore 2025-08-12 13:36:31 - browse：89667

Illumina said Monday afternoon that its board of directors had approved a spin-off of its cancer test subsidiary Grail, signaling that a nearly four-year-long, $8 billion saga will finally draw to a close this month.

Shares in the newly independent Grail are expected to be distributed on June 24, Illumina said in a statement. Illumina will retain a 14.5% stake in the company, which will trade under the ticker $GRAL.

It’s the second time Illumina has spun off Grail, which initially began as a unit within the DNA sequencing giant in 2015. Illumina turned it into an independent company the following year but then agreed to reacquire it for $8 billion in September 2020.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： ChatGPT in medicine: STAT answers readers' burning questions
Next article： 'Ancient DNA,' 23andMe reveal African American ancestries

leisure time

WSS

Nearly two

Study: Lilly Alzheimer's therapy slowed patients' cognitive decline

For BCIs, commercial hurdles may be bigger than scientific ones

Treeline, Josh Bilenker's next biotech, is cloaked in mystery

Colonoscopy at 40? Study finds a possible benefit

New guidelines on severe brain injury complicate already difficult decisions

knowledge

explore

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

explore

Continuity nursing helped my family in our darkest PICU moments

OTC birth control: A brief history of over the counter pill design

Duchenne breakthrough therapy leaves behind pioneering families

CDC concerned about possible undetected monkeypox spread in U.K.

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Mega Millions jackpot rises to record $1.55 billion for Tuesday's drawing

How to save PrEP access — and even expand it

#NeedHerScience: shining a light on gender disparities in medicine

Guidelines to prevent youth baseball injuries need more muscle

ER docs worry over extreme heat as a 'mass casualty event'

entertainment

#NeedHerScience: shining a light on gender disparities in medicine

Why drug prescriptions should include diagnoses

The drug industry sees a key ally in the Senate prevail

CDC: Uninsured rate hit 'record low' right as states cut Medicaid

Trump drops motion seeking removal of DA probing efforts to overturn 2020 election in Georgia

Cloning humans is technically possible. It's curious no one has tried

focus

leisure time

Wikipedia

focus